Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION: Adalimumab in plaque psoriasis – effects on TNF-α and MAP kinases in psoriatic skin
2006-001684-34Phase 2Completed
- Sponsor
- Knud Kragballe, Dermatological Department, Ã…rhus Sygehus (Hospital)
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in plaque psoriasis, sponsored by Knud Kragballe, Dermatological Department, Ã…rhus Sygehus (Hospital). Primary endpoint: Proportion of patients with normalized TNF-α, P-38, MK2, and MSK1 levels in psoriatic skin lesions at day 84. Started May 2006; status: completed.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2006-001684-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001684-34.